Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | WDR5 | P61964 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20330094 | 0.94 | L3MBTL1 (0.62) | L3MBTL1HPGDHTTCYP1A2CYP3A4 | |
| SCHEMBL881471 | 0.92 | L3MBTL1 (0.70) | L3MBTL1HPGDHTTCYP1A2CYP3A4 | |
| SCHEMBL6883728 | 0.85 | L3MBTL1 (0.82) | L3MBTL1HPGDHTTCYP1A2CYP3A4 | |
| SCHEMBL9923551 | 0.85 | L3MBTL1 (0.65) | L3MBTL1HPGDHTTCYP1A2CYP3A4 | |
| SCHEMBL7917839 | 0.85 | MAPT (0.61) | L3MBTL1HPGDALDH1A1PARP10 | |
| SCHEMBL7923893 | 0.82 | LTA4H (0.53) | L3MBTL1DRD2DRD4DRD3PARP10 | |
| SCHEMBL7928218 | 0.81 | L3MBTL1 (0.76) | L3MBTL1HPGDMEN1KMT2APOLB | |
| SCHEMBL21093512 | 0.81 | L3MBTL1 (0.61) | L3MBTL1HPGDHTTCYP1A2CYP3A4 | |
| SCHEMBL13948678 | 0.81 | L3MBTL1 (0.61) | L3MBTL1HPGDHTTCYP1A2CYP3A4 | |
| SCHEMBL22266211 | 0.81 | L3MBTL1 (0.51) | L3MBTL1HPGDMEN1KMT2AWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| EP-1268484-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
| WO-2001068652-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | L3MBTL1 3041/4885HPGD 283/4885HTT 254/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | L3MBTL1 3041/4885HPGD 283/4885HTT 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.